All News
Lifestyle and Incretin Therapy Advice for Rheumatologists
As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to pharmacotherapy - a reversal of the traditional model. This has with direct implications for how we counsel obese patients we start or co-manage on these agents.
Read ArticleGlucocorticoids: Use vs.Toxicity
This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.
Read ArticleMentshlichkeit* (8.7.2026)
Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com.
Read ArticleJAMA Review of Hip Fracture
The July 16th edition of JAMA reviews the highly prevalent problem of hip fractures - a major global health burden: 14.2 million occur worldwide annually (280,000 in the US), with global incidence higher in women (833.9/100,000) than men (510.0/100,000). Lifetime risk at age 50 is 22.9% for women, 10.7% for men. Mortality is substantial.
Read ArticleACP Position Paper on Dietary Supplements
More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives.
Read ArticleDo we need Better Strategies to Prevent Osteoporotic Fractures?
In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.
Read Article


